A comparison of pivmecillinam/pivampicillin and co-trimoxazole in hospitalized patients with acute exacerbations of chronic bronchitis.
Forty-nine hospitalized patients with acute exacerbations of chronic bronchitis were randomly allocated a ten-day course of either pivmecillinam/pivampicillin or co-trimoxazole. Both treatments were equally effective clinically (pivmecillinam/pivampicillin successful in 72% of cases; co-trimoxazole in 70%) and in their ability to eradicate pus from sputum (pivmecillinam/pivampicillin 84%; co-trimoxazole 74%). One patient taking co-trimoxazole ceased therapy because of persistent nausea and vomiting. No side-effects were observed in the pivmecillinam/pivampicillin group.
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000560:Amdinocillin / Q000627:therapeutic use*; D000561:Amdinocillin Pivoxil / Q000627:therapeutic use*; D000667:Ampicillin / Q000031:analogs & derivatives*; D001991:Bronchitis / Q000188:drug therapy*; D002175:Candida / Q000302:isolation & purification; D004338:Drug Combinations / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006190:Haemophilus / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008875:Middle Aged; D010917:Pivampicillin / Q000627:therapeutic use*; D011549:Pseudomonas / Q000302:isolation & purification; D011897:Random Allocation; D013183:Sputum / Q000382:microbiology; D013296:Streptococcus pneumoniae / Q000302:isolation & purification; D013420:Sulfamethoxazole / Q000627:therapeutic use*; D014295:Trimethoprim / Q000627:therapeutic use*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D004338:Drug Combinations; D010917:Pivampicillin; D000561:Amdinocillin Pivoxil; D000667:Ampicillin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole; D000560:Amdinocillin